Brostallicin
- Generic Name
- Brostallicin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H35BrN12O5
- CAS Number
- 203258-60-0
- Unique Ingredient Identifier
- RPC6R41K4I
- Indication
Investigated for use/treatment in solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 48
- Registration Number
- NCT01091454
- Locations
- ๐บ๐ธ
Illinois CancerCare - Havana, Havana, Illinois, United States
๐บ๐ธMason District Hospital, Havana, Illinois, United States
๐บ๐ธRiverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
Brostallicin Clinical Trial for Myxoid Liposarcoma
Phase 2
- Conditions
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Systems Medicine LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00633165
- Locations
- ๐บ๐ธ
Sarcoma Oncology Center, Santa Monica, California, United States
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
Phase 2
- Conditions
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2014-08-08
- Target Recruit Count
- 118
- Registration Number
- NCT00410462
- Locations
- ๐ณ๐ฑ
Leiden University Medical Center, Leiden, Netherlands
Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2014-01-16
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00060203
- Locations
- ๐บ๐ธ
Ireland Cancer Center, Cleveland, Ohio, United States
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-18
- Target Recruit Count
- 64
- Registration Number
- NCT00041249
- Locations
- ๐ฉ๐ช
Klinikum Grosshadern der Ludwig-Maximilians Universitaet Muenchen, Munich, Germany
๐ซ๐ทInstitut Gustave Roussy, Villejuif, France
๐ฉ๐ชUniversitaets-Krankenhaus Eppendorf, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath